IGXT Corporate Presentation.

1. Innovation In Drug Delivery
An introduction to unique pharmaceutical delivery technologies
May 2015
TSX-V: IGX
OTCQX: IGXT

2. FORWARD LOOKING STATEMENTS
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our
current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words
such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other characterizations of future events or circumstances are
forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and
uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic
Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive
products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw
materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings,
fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission and the Ontario Securities Commission. IntelGenx undertakes no obligation to update or
revise any forward-looking statement.
2

3. Rapid and convenient dosage form for more
immediate activity
Programmable drug release over an extended
period of time
Controlled absorption in the oral cavity
to maximize bioavailability
INTELGENX DEVELOPS FASTER AND MORE EFFICIENT DRUG DELIVERY
SYSTEMS FOR TOP PHARMACEUTICALS
INNOVATIVE DELIVERY TECHNOLOGY
VERSATAB™ ADVERSA™VERSAFILM™
FOCUSING ON ORAL DRUG DELIVERY
3

4. UNIQUE TECHNOLOGIES
TECHNOLOGY FOCUSED
Develop novel and high performance drug delivery systems – focus on oral film products.
TARGET HIGH-VALUE DIFFERENTIATED OPPORTUNITIES
INNOVATIVE DELIVERY TECHNOLOGY
• Use proprietary drug delivery technologies to develop products offering a
therapeutic benefit to patients.
• Identify unique drug-repurposing opportunities.
• Pursue high technological entry barrier products and first-to-file opportunities.
• Develop products addressing unmet therapeutic needs.
4

5. PROVIDE COMPREHENSIVE PHARMACEUTICAL SERVICES TO INDUSTRY
PARTNERS:
 Pharmaceutical Research and Development
 Clinical monitoring; clinical supply manufacturing
 Regulatory services
 Process development and technology transfer
 Commercial product supply
REVENUE STREAM CONSISTING OF:
 Upfront payments
 R&D milestone payments
 Sales milestone payments
 Royalties on sales
 Manufacturing revenue
VALUE PROPOSITION
5

6. PRODUCT PORTFOLIO
A ROBUST PRODUCT PIPELINE ACROSS 3 TECHNOLOGY PLATFORMS
PRECLINICAL PILOT STUDY PIVOTAL STUDY FILING LAUNCH
Forfivo XL® Major Depressive
Disorder
INT0001 Hypertension
INT0024
Idiopathic Pulmonary
Fibrosis (Pacific)
INT0008 Migraine (RedHill)
INT0027
Opioid Dependence
(Par)
INT0037 Undisclosed (Par)
INT0039 Undisclosed (Par)
INT0007 Erectile Dysfunction
INT0036
Central Nervous System
(CNS)
INT0010 Pain
Launched Q4 2012
Q1 2013
Q3 2013

7. INTELGENX PARTNERSHIPS
INTELGENX HAS STRATEGIC PARTNERSHIPS IN PLACE WITH MULTIPLE COMPANIES
7

8. VersaTabTM
Addressable market for
pipeline VersaTabTM
products.
VersaFilmTM
Opportunity to convert
existing tablet market
into film technology
$8.1
Billion
$2.7
Billion
ADDRESSABLE MARKET FOR PRODUCT PIPELINE
SIGNIFICANT MARKET POTENTIAL
~$11BCombined,
addressable market
for product pipeline
25%
75%
$11bTotal addressable
market

9. $1.2B
2013 Metroprolol
Sales
$1.1B
Pentoxifylline - NAC
• Linear release profile;
controlled erosion of inactive
cover layers
• Multiple actives with
independent release profiles
• Separation of active
ingredients - avoidance of
chemical incompatibility in
fixed-dose combinations
• Cost-effective manufacturing
Depression Hypertension
Idiopathic Pulmonary
Fibrosis Addressable
Market
$391M
Wellbutrin XL &
Bupropion XL Sales
PRECLINICAL PILOT STUDY
PIVOTAL
STUDY
FILING LAUNCH
Forfivo XL
Major
Depressive
Disorder
INT0001 Hypertension
INT0024
Idiopathic
Pulmonary
Fibrosis
(Pacific)
VERSATAB®
PRODUCTS
Launched Q4 2012®
VersaTab®
Addressable
Market
~$2.7B
MULTILAYER TABLET TECHNOLOGY
VERSATAB TM
9

10. $3.0B
Current Market for
Bupropion
• High dose version of
Wellbutrin XL®
• Provides a once-daily,
bupropion 450 mg dose in a
single tablet
• Indicated for the treatment of
major depressive disorder
• Launched commercially
October 2012 in partnership
with Edgemont
Pharmaceuticals
• Paragraph IV litigation with
with Wockhardt settled
$236M
Wellbutrin XL®
Market
$2.7M
2013 Sales
Forfivo XL
FORFIVO XL® SCRIPT GROWTH
®
VERSATAB TM
VersaTab®
Addressable
Market
~$2.7B
FORFIVO XL® COMMERCIALIZATION GROWTH OPPORTUNITY
10
$0
$300,000
$600,000
$900,000
$1,200,000
$1,500,000
$1,800,000
0
1,000
2,000
3,000
4,000
5,000
Over $1.5M
March 2015
Gross Sales
3,893
March 2015
Prescriptions

11. VersaFilm™
Rapidly disintegrating pharmaceutical films
for buccal or systemic drug delivery
VersaFilm
Addressable
Market
~$8.1B
®
Improved product performance:
• Fast delivery translates into
rapid onset of action
• Improved bioavailability
• Buccal (topical) or systemic
drug exposure
Improved patient compliance:
• Convenient delivery improving
compliance for pediatric and
geriatric patients where
swallowing is an issue
Increased barrier for generic
competition:
• Limited number of competitors
ADVANTAGES OF FILM TECHNOLOGY
VERSAFILM TM
11

12. $1.3B
• Demonstrated ability to
achieve bioequivalence
• Two applications currently
under review at FDA:
one ANDA, and one
505(b)(2)NDA
• Comprehensive
VersaFilm™ development
pipeline
• Limited number of
competitors, strong IP
position
Opioid Dependence Migraine Erectile Dysfunction
$230M
Targeted Rizatriptan
Market
Targeted Cialis
Sales
®
$1.6B
Targeted Suboxone
Sales
®
VersaFilm
Addressable
Market
~$8.1B
®
ADDRESSABLE MARKETS
VERSAFILM TM
12
PRECLINICAL PILOT STUDY
PIVOTAL
STUDY
FILING LAUNCH
INT0008
Migraine
(RedHill)
INT0027
Opioid
Dependence
(Par)
INT0007
Erectile
Dysfunction
INT0036 CNS
INT0037
Undisclosed
(Par)
INT0039
Undisclosed
(Par)
Q1 2013 2015
VERSAFILM
PRODUCTS
Q3 2013 2017
Q4 2016 Q4 2017

13. Suboxone® Rx Quantities (Millions)
0
20
40
60
80
2008 2009 2010 2011 2012 2013
Film Tablet
• Demonstrated ability to
achieve bioequivalence
• Two applications currently
under review at FDA:
one ANDA, and one
505(b)(2)NDA
• Comprehensive
VersaFilm™ development
pipeline
• Limited number of
competitors, strong IP
position
VersaFilm
Addressable
Market
~$8.1B
®
ATTRACTIVE LIFECYCLE MANAGEMENT OPPORTUNITY
VERSAFILM TM
13
Suboxone®
SublingualFilm
Suboxone®
SublingualTablets

14. 0.
0.35
0.7
1.05
1.4
0. 12. 24. 36. 48. 60. 72.
Meanconcentration(ng/mL)
Time (hrs)
Buprenorphine plasma profile
Test product Test productReference product
Suboxone
Addressable
Market
~$1.6B
®
Completed development with
successful pivotal
bioequivalency study.
Abbreviated New Drug
Application (ANDA)
submitted to FDA in July
2013.
Marketing approval
anticipated 2016.
Attractive partnership deal
with Par Pharmaceutical
P4 litigation with Reckitt
Benckiser progressing well
0.
30.
60.
90.
120.
150.
0. 6. 12. 18. 24.
Meanconcentration(pg/mL)
Time (hrs)
Naloxone plasma profile
Test product reference product (Suboxone 8/2mg)
OPIOD DEPENDENCE - BUPRENORPHINE/NALOXONE
VERSAFILM TM
14

15. Rizatriptan®
Addressable
Market
$230M
Successfully completed
development and stability
testing
Filed 505(b)(2)NDA in March
2013
Co-development and
licensing agreement in place
with RedHill Biopharma
Negotiations with
commercialization partner
ongoing
0.0
4.5
9.0
13.5
18.0
0.0 3.0 6.0 9.0 12.0 15.0
RizatriptanPl.Conc.(ng/mL)
Time (hrs)
VersaFilm Rizatriptan
Maxalt MLT®
Orally disintegrating film containing Rizatriptan bioequivalent
with orally disintegrating tablet (Maxalt MLT®)
MIGRAINE FILM BIOEQUIVALENT TO MAXALT MLT®
VERSAFILM TM
15

16. Cialis®
Addressable
Market
~$1.3B
CP pending for OTC
approval
Formulation development
ongoing.
Worldwide patent application.
Pilot BE study on 10 mg
strength suggests BE with
RLD.
Confirmatory pilot BE study
on 20 mg strength
completed.
Successful pilot BE study (10 mg strength)
BIOEQUIVALENCE ACHIEVED VS. CIALIS® TABLETS
VERSAFILM TM
16

17. Schizophrenia
Market1~$5.2B
CNS FILM INT0036 – A fast acting version of an existing schizophrenia treatment.
VERSAFILM TM
Successfully completed pilot
scale Phase I study
INT0036 demonstrated a
significantly improved
pharmacokinetic profile
against the reference product
1 According to Datamonitor
Healthcare schizophrenia
forecast published July 13,
2012
0
7,500
15,000
22,500
30,000
0 15 30 45 60
RizatriptanPl.Conc.(ng/mL)
Time (min)
VersaFilm INT0036
RLD

18. A STRONG PLATFORM FOR GROWTH AND INNOVATION
VERSAFILM TM
• Addressable market of approximately $8.1 billion identified to-date
• Strong intellectual property protection
• Successful pivotal bioequivalency studies
• Three applications for film products awaiting FDA approval
• Limited number of competitors
• Life cycle management opportunity

19. DEVELOPING FILM MANUFACTURING CAPABILITIES TO INCREASE PROFITABILITY
OPERATIONAL INITIATIVES
19
• Significantly increase IntelGenx' revenue stream
• Improve protection of IntelGenx' IP.
• Eliminate dependency on 3rd party manufacturing partners
• Provide full service from inception to product supply (one-stop-shopping).
• Increase R&D capabilities and investments with expanded laboratories and
technologies.

20. Develop
• 2014, Identify a second
supplier for Rizatriptan
• 2014, Submit application for
Rizatriptan in Europe
• 2014, Acceptance of ANDA for
INT0027 triggering a milestone
payment from Par
• 2014, Clarity on ForFivo XL
litigation with WockHardt
2014 2015 2016 2017
SUGGESTS NEAR TERM CATALYSTS
KEY MILESTONES
Position
• 2015, Anticipated approval for migraine
VersaFilmTM
• 2015, Anticipated submission of ANDA for
Antihypertensive VersaTabTM
• 2016, Anticipated tentative approval for
opioid dependence VersaFilm™
• 2016, Commence manufacturing capabilities
of VersaFilm™
Grow
• 2016, Anticipated submission of
505(b)(2) NDA for ED VersaFilm™
• 2017, Anticipated launch for opioid
dependence VersaFilm™
• 2017, Anticipated approval for ED
VersaFilm™
20

21. Horst G. Zerbe, Ph.D.
Chairman, President and CEO
• Founder of IntelGenx
• 30+ years Industry Experience
• Holds over 40 patents in drug delivery, and numerous
scientific publications
• Previously President Smartrix Tech. Inc. and VP R&D at
LTS Lohmann, USA
Paul Simmons, AFCA
Chief Financial Officer
Nadine Paiement, M.Sc.
Director R&D
• 25 + years multinational business and finance experience
• Proven track record of exceeding targets in delivering
corporate growth
• Held CFO and VP Finance positions with several European
corporations
• Co-inventor of IntelGenx Trilayer Technology
• 10 years experience in product development and technology
transfer
• Previously R&D Manager at Smartrix Tech. Inc.
65+ YEARS OF COMBINED INDUSTRY EXPERIENCE
VISIONARY, EXPERIENCED LEADERSHIP
21
John Durham, B.Sc.
Vice President, Manufacturing Operations
• 20+ years experience in pharmaceutical manufacturing,
quality management, product development
• Held executive positions with several Canadian and US
companies
• Previously COO at Labopharm Inc. and President at Draxis
Pharma

22. CORE TECHNOLOGIES ADDRESS LARGE MARKET POTENTIAL
A SOLID PLATFORM FOR GROWTH
• Continue to expand commercialization efforts of Forfivo XL® and drive revenue
growth
• Advance pipeline products towards commercialization
• Continue to develop commercialization relationships
• Leverage VersaFilm™ manufacturing expertise to provide full service
VERSATAB™ ADVERSA™VERSAFILM™
22

23. Innovation In Drug Delivery
Thank You
TSX-V: IGX
OTCQX: IGXT